FENC

Fennec Pharmaceuticals Inc

May 18 • 03:35PM ET

9.51

-0.24 -2.46 %

Healthcare • Biotechnology • USA • Small • NASD

May 15, 12:08 PMFennec beats Q1 2026 estimates as PEDMARK sales jump 73% and company turns cash-flow positive

Peers: NVCT ORIC ADCT KPTI VERU

| Held by: IWM VTI IWN VTWO IWC IWO OMFS RSSL VTWV VTWG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.30	Insider Own	14.57%	Shs Outstand	34.54M	Perf Week	33.94%
Market Cap	330.35M	Forward P/E	9.49	EPS next Y	1.00	Insider Trans	-17.72%	Shs Float	29.67M	Perf Month	40.06%
Enterprise Value	290.17M	PEG	-	EPS next Q	0.01	Inst Own	57.95%	Short Float	3.57%	Perf Quarter	9.56%
Income	-8.73M	P/S	6.48	EPS this Y	178.10%	Inst Trans	4.60%	Short Ratio	4.93	Perf Half Y	23.67%
Sales	51.00M	P/B	8.72	EPS next Y	266.46%	ROA	-14.77%	Short Interest	1.06M	Perf YTD	23.51%
Book/sh	1.09	P/C	8.22	EPS next 5Y	-	ROE	-54.93%	52W High	10.17 -6.49%	Perf Year	39.04%
Cash/sh	1.16	P/FCF	-	EPS past 3/5Y	27.71% 14.90%	ROIC	-23.18%	52W Low	5.65 68.32%	Perf 3Y	28.17%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	207.52% 204.69%	Gross Margin	92.23%	Volatility	12.31% 7.02%	Perf 5Y	44.97%
Dividend TTM	-	EV/Sales	5.69	EPS Y/Y TTM	42.43%	Oper. Margin	-11.87%	ATR (14)	0.61	Perf 10Y	211.80%
Dividend Ex-Date	-	Quick Ratio	6.78	Sales Y/Y TTM	64.98%	Profit Margin	-17.12%	RSI (14)	73.49	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.98	EPS Q/Q	113.27%	SMA20	32.69%	Beta	0.99	Target Price	15.17
Payout	-	Debt/Eq	0.00	Sales Q/Q	72.64%	SMA50	37.15%	Rel Volume	1.48	Prev Close	9.75
Employees	35	LT Debt/Eq	0.00	Earnings	May 14 BMO	SMA200	19.89%	Avg Volume	215.19K	Price	9.51
IPO	Oct 22, 2003	Option/Short	Yes / Yes	EPS/Sales Surpr.	122.78% 8.64%	Trades		Volume	298,921	Change	-2.46%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-12-26	Initiated	B. Riley Securities	Buy	$16
Jan-09-26	Initiated	Piper Sandler	Overweight
Nov-22-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$9 → $12
Sep-07-22	Initiated	CapitalOne	Overweight	$11
Aug-08-22	Resumed	Craig Hallum	Buy	$14
Jun-05-20	Initiated	Cantor Fitzgerald	Overweight	$18
Oct-11-18	Initiated	Goldman	Buy

May-14-26 07:03PM	Fennec Pharmaceuticals Inc (FENC) Q1 2026 Earnings Call Highlights: Record Sales Surge and ... (GuruFocus.com) +36.48% +5.52%
05:11PM	Fennec Pharmaceuticals Inc. Q1 2026 Earnings Call Summary (Moby)
08:47AM	Fennec Pharmaceuticals Shares Rise After Earnings and Revenue Beat Forecasts (FENC) (InvestorsHub)
06:30AM	Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
May-07-26 06:36AM	Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026 (GlobeNewswire)
04:30PM	Loading…
Apr-21-26 04:30PM	Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting (GlobeNewswire)
Apr-07-26 07:03AM	Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center (GlobeNewswire)
Mar-31-26 06:00AM	Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.59%
Mar-25-26 08:30AM	Fennec Pharmaceuticals Inc. Q4 2025 Earnings Call Summary (Moby)
Mar-24-26 03:02PM	Fennec Pharmaceuticals Inc (FENC) Q4 2025 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com) -19.19%
01:20PM	Fennec Pharmaceuticals Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses (Newsfile)
07:00AM	Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Mar-18-26 07:08AM	Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026 (GlobeNewswire)
Mar-16-26 08:08AM	Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation (GlobeNewswire)
Mar-05-26 10:00AM	Earnings Preview: Gossamer Bio (GOSS) Q4 Earnings Expected to Decline (Zacks)
07:05AM	Loading…
Mar-04-26 07:05AM	Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute (GlobeNewswire)
Mar-02-26 10:00AM	Adherex Technologies Inc. (FENC) Earnings Expected to Grow: What to Know Ahead of Q4 Release (Zacks)
07:15AM	Zymeworks Inc. (ZYME) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
Feb-26-26 08:15AM	Certara, Inc. (CERT) Q4 Earnings Lag Estimates (Zacks)
Feb-24-26 11:00AM	Apellis Pharmaceuticals, Inc. (APLS) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
Feb-20-26 07:03AM	Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK in Treating Adults with Head & Neck Cancers (GlobeNewswire)
Feb-12-26 08:00AM	Here Are Thursdays Top Wall Street Analyst Research Calls: BP Plc., Borg Warner, Generac, Kraft-Heinz, MercadoLibre, Pfizer, Shopify, Valvoline, and More (24/7 Wall St.)
Dec-26-25 05:44PM	Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC) (GlobeNewswire) +5.48%
Dec-09-25 07:00AM	Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors (GlobeNewswire)
Dec-02-25 07:01AM	Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK in Japan to Reduce Cisplatin-Induced Hearing Loss (GlobeNewswire)
Nov-26-25 05:59AM	Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-19-25 07:03AM	Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption (GlobeNewswire) -6.51%
Nov-18-25 08:30AM	Fennec Pharmaceuticals Announces Closing of Private Offering of Common Shares in Canada (GlobeNewswire)
Nov-17-25 04:15PM	Fennec Pharmaceuticals Announces Closing of Offering of Common Shares (GlobeNewswire) +11.32%
Nov-13-25 11:11PM	Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada (GlobeNewswire)
11:07PM	Loading…
11:07PM	Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares (GlobeNewswire)
05:10PM	Adherex Technologies Inc. (FENC) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:08PM	Fennec Pharmaceuticals Announces Proposed Offering of Common Shares (GlobeNewswire)
04:01PM	Fennec Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-12-25 05:25PM	Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Nov-04-25 06:00PM	Niagen Bioscience (NAGE) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
Oct-30-25 10:00AM	Adherex Technologies Inc. (FENC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-22-25 10:19AM	Are Options Traders Betting on a Big Move in Fennec Pharmaceuticals Stock? (Zacks)
Oct-15-25 04:20AM	New Strong Sell Stocks for Oct. 15th (Zacks) +5.86%
Oct-06-25 09:40AM	Day One Biopharmaceuticals (DAWN) Moves 7.0% Higher: Will This Strength Last? (Zacks)
Sep-19-25 09:43AM	Is the Options Market Predicting a Spike in Adherex Technologies Stock? (Zacks)
Aug-14-25 07:20AM	Adherex Technologies Inc. (FENC) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -6.37%
06:08AM	Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update (GlobeNewswire)
Aug-13-25 05:15PM	Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-12-25 05:10PM	Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +12.00%
Aug-11-25 08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:12AM	Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025 (GlobeNewswire)
Aug-07-25 07:05PM	Concentra Group (CON) Matches Q2 Earnings Estimates (Zacks)
Jul-31-25 09:40AM	Are Medical Stocks Lagging Editas Medicine (EDIT) This Year? (Zacks)
Jul-15-25 08:50AM	Recent Price Trend in Adherex Technologies (FENC) is Your Friend, Here's Why (Zacks)
Jun-03-25 04:31PM	Fennec Announces Results of Annual Meeting (GlobeNewswire)
May-14-25 10:51AM	The Joint Misses Q1 Earnings Estimates on Rising Expenses (Zacks)
03:07AM	Fennec Pharmaceuticals Inc (FENC) Q1 2025 Earnings Call Highlights: Strong Sales Growth Amid ... (GuruFocus.com)
May-13-25 11:33PM	Q1 2025 Fennec Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
11:06AM	Acadia Healthcare Q1 Earnings Top Estimates on Rising Admissions (Zacks)
07:15AM	Adherex Technologies Inc. (FENC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:03AM	Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-12-25 05:10PM	Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +5.38%
May-09-25 06:26PM	Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised) (Zacks)
May-08-25 06:05PM	AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:17PM	Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 (GlobeNewswire)
May-07-25 05:35PM	Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Zacks)
Apr-30-25 09:55AM	Wall Street Analysts See an 113.25% Upside in Adherex Technologies (FENC): Can the Stock Really Move This High? (Zacks)
Apr-10-25 09:35AM	Down -22.15% in 4 Weeks, Here's Why Adherex Technologies (FENC) Looks Ripe for a Turnaround (Zacks)
Mar-21-25 10:21AM	Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last? (Zacks)
Mar-11-25 03:00AM	Fennec Pharmaceuticals Inc (FENC) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
12:31AM	Q4 2024 Fennec Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-10-25 06:03AM	Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -11.19%
Mar-06-25 04:22PM	Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025 (GlobeNewswire)
Feb-07-25 07:00AM	Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI In Germany (GlobeNewswire)
Dec-20-24 06:16AM	Fennec Pharmaceuticals Announces Pedmarqsi Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales (GlobeNewswire)
Dec-19-24 06:13AM	Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management (GlobeNewswire)
Dec-12-24 07:01AM	Fennec Pharmaceuticals to Participate in Upcoming Investor Conference (GlobeNewswire)
Nov-13-24 06:27AM	Fennec Pharmaceuticals to Participate in Upcoming Investor Conference (GlobeNewswire) +5.91%
Nov-09-24 02:00AM	Fennec Pharmaceuticals Inc (FENC) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
Nov-07-24 06:13AM	Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -11.92%
Oct-31-24 06:23AM	Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire)
Oct-28-24 06:23AM	Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company's Next Stage of Growth (GlobeNewswire) +11.56%
Sep-05-24 06:56AM	Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-14-24 01:57AM	Q2 2024 Fennec Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -8.89%
Aug-13-24 06:05AM	Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -6.40%
Aug-06-24 04:31PM	Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024 (GlobeNewswire)
Aug-05-24 06:26AM	Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director (GlobeNewswire)
Jul-29-24 06:15AM	3 Dirt-Cheap Stocks Under $10 That Could EXPLODE! (InvestorPlace)
Jul-15-24 08:32AM	Implied Volatility Surging for Fennec (FENC) Stock Options (Zacks)
Jul-01-24 06:00AM	Fennec Pharmaceuticals Announces Management Change (GlobeNewswire)
Jun-25-24 04:35PM	Fennec Announces Results of Annual Meeting (GlobeNewswire)
May-15-24 08:44AM	HC Wainwright Adjusts Fennec Pharmaceuticals Price Target to $15 From $18, Maintains Buy Rating (MT Newswires)
May-14-24 10:53AM	FENC Stock Earnings: Fennec Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) -26.75%
07:20AM	Fennec Pharmaceuticals Swings to Q1 Profit on Higher Sales, Licensing Revenue (MT Newswires)
06:03AM	Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-07-24 06:15PM	Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024 (GlobeNewswire)
Apr-23-24 08:01AM	Fennec Pharmaceuticals Insider Sold Shares Worth $414,472, According to a Recent SEC Filing (MT Newswires)
Apr-05-24 07:00PM	Insider Sell: CEO Rosty Raykov Sells 88,583 Shares of Fennec Pharmaceuticals Inc (FENC) (GuruFocus.com)
Mar-27-24 07:00PM	Chief Financial Officer Robert Andrade Sells 13,975 Shares of Fennec Pharmaceuticals Inc (FENC) (GuruFocus.com)
Mar-26-24 01:00AM	Chief Financial Officer Robert Andrade Sells Shares of Fennec Pharmaceuticals Inc (FENC) (GuruFocus.com)
Mar-22-24 09:49AM	Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2023 Earnings Call Transcript (Insider Monkey)
05:04AM	Q4 2023 Fennec Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-21-24 02:52PM	FENC Stock Earnings: Fennec Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
06:00AM	Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)

Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on the development and commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in pediatric patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

CEO & DirectorMr. Jeffrey S. Hackman

Chief Financial OfficerMr. Robert C. Andrade

Ph.D.Dr. Pierre S. Sayad M.S.

Chief Commercial OfficerMr. Terry Evans

Chief Strategy OfficerMs. Christiana Cioffi M.B.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RALLIS CHRIS A	Director	May 11 '26	Option Exercise	2.44	14,344	34,999	71,423	May 12 04:05 PM
RALLIS CHRIS A	Director	May 11 '26	Sale	7.04	8,346	58,756	63,077	May 12 04:05 PM
CHRIS A RALLIS	Director	May 11 '26	Proposed Sale	7.05	8,346	58,833		May 11 04:16 PM
Raykov Rosty	Director	May 01 '26	Option Exercise	2.45	15,598	38,215	132,232	May 01 05:00 PM
Raykov Rosty	Director	Apr 30 '26	Option Exercise	0.00	2,778	0	116,634	May 01 05:00 PM
Raykov Rosty	Director	May 01 '26	Sale	6.47	10,781	69,753	121,451	May 01 05:00 PM
ROSTISLAV RAYKOV	Director	May 01 '26	Proposed Sale	6.47	10,781	69,762		May 01 04:15 PM
Evans Terry L	Chief Commercial Officer	Apr 30 '26	Option Exercise	0.00	168	0	20,847	May 01 04:05 PM
Cioffi Christiana Marie	Chief Strategy Officer	Apr 30 '26	Option Exercise	0.00	155	0	24,020	May 01 04:05 PM
Hackman Jeffrey S.	Chief Executive Officer	Apr 30 '26	Option Exercise	0.00	1,159	0	61,666	May 01 04:05 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	Apr 30 '26	Option Exercise	0.00	1,703	0	287,566	May 01 04:05 PM
Sayad Pierre Sargis	Chief Medical Officer	Apr 30 '26	Option Exercise	0.00	168	0	20,847	May 01 04:05 PM
Cioffi Christiana Marie	Chief Strategy Officer	Mar 31 '26	Option Exercise	0.00	17,264	0	21,964	Apr 02 04:05 PM
Cioffi Christiana Marie	Chief Strategy Officer	Mar 28 '26	Option Exercise	0.00	1,901	0	23,865	Apr 02 04:05 PM
Hackman Jeffrey S.	Chief Executive Officer	Mar 31 '26	Option Exercise	0.00	17,854	0	46,564	Apr 02 04:05 PM
Hackman Jeffrey S.	Chief Executive Officer	Mar 28 '26	Option Exercise	0.00	13,943	0	60,507	Apr 02 04:05 PM
Raykov Rosty	Director	Apr 01 '26	Option Exercise	2.45	15,598	38,215	124,802	Apr 02 04:05 PM
Raykov Rosty	Director	Apr 01 '26	Sale	6.31	10,946	69,069	113,856	Apr 02 04:05 PM
Sayad Pierre Sargis	Chief Medical Officer	Mar 31 '26	Option Exercise	0.00	18,627	0	18,627	Apr 02 04:05 PM
Sayad Pierre Sargis	Chief Medical Officer	Mar 28 '26	Option Exercise	0.00	2,052	0	20,679	Apr 02 04:05 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	Mar 31 '26	Option Exercise	0.00	16,937	0	273,593	Apr 02 04:05 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	Mar 28 '26	Option Exercise	0.00	12,270	0	285,863	Apr 02 04:05 PM
Evans Terry L	Chief Commercial Officer	Mar 31 '26	Option Exercise	0.00	18,627	0	18,627	Apr 02 04:05 PM
Evans Terry L	Chief Commercial Officer	Mar 28 '26	Option Exercise	0.00	2,052	0	20,679	Apr 02 04:05 PM
ROSTISLAV RAYKOV	Director	Apr 01 '26	Proposed Sale	6.31	10,946	69,073		Apr 01 04:38 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	Mar 26 '26	Option Exercise	5.10	13,072	66,667	256,656	Mar 26 04:30 PM
Cioffi Christiana Marie	Chief Strategy Officer	Mar 26 '26	Option Exercise	4.23	4,700	19,881	4,700	Mar 26 04:29 PM
Raykov Rosty	Director	Mar 02 '26	Option Exercise	2.45	15,598	38,215	114,075	Mar 03 04:05 PM
Raykov Rosty	Director	Mar 02 '26	Sale	8.36	10,079	84,260	103,996	Mar 03 04:05 PM
ROSTISLAV RAYKOV	Director	Mar 02 '26	Proposed Sale	8.37	10,079	84,354		Mar 02 05:07 PM
Hackman Jeffrey S.	Chief Executive Officer	Feb 18 '26	Option Exercise	0.00	13,710	0	28,710	Feb 19 06:44 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	Feb 18 '26	Option Exercise	0.34	29,735	9,996	242,393	Feb 19 06:43 PM
Raykov Rosty	Director	Feb 02 '26	Option Exercise	2.45	15,598	38,215	108,826	Feb 02 04:54 PM
Raykov Rosty	Director	Feb 02 '26	Sale	7.76	10,349	80,308	98,477	Feb 02 04:54 PM
ROSTISLAV RAYKOV	Director	Feb 02 '26	Proposed Sale	7.76	10,349	80,339		Feb 02 04:32 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	Jan 23 '26	Option Exercise	2.45	10,000	24,500	211,100	Jan 23 04:56 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	Jan 15 '26	Option Exercise	2.45	10,000	24,500	201,100	Jan 15 04:05 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	Jan 07 '26	Option Exercise	2.45	14,184	34,751	191,100	Jan 07 04:28 PM
Raykov Rosty	Director	Jan 02 '26	Option Exercise	2.45	15,598	38,215	98,332	Jan 05 04:05 PM
Raykov Rosty	Director	Jan 02 '26	Sale	7.60	10,312	78,371	88,020	Jan 05 04:05 PM
ROSTISLAV RAYKOV	Director	Jan 02 '26	Proposed Sale	7.61	10,312	78,471		Jan 02 04:19 PM
Southpoint Capital Advisors LP	10% Owner	Dec 24 '25	Sale	7.50	1,000,000	7,500,000	2,744,741	Dec 29 04:34 PM
Raykov Rosty	Director	Dec 05 '25	Sale	7.54	10,000	75,400	77,526	Dec 05 06:41 PM
ROSTISLAV RAYKOV	Director	Dec 05 '25	Proposed Sale	7.54	10,000	75,444		Dec 05 05:13 PM
Southpoint Capital Advisors LP	10% Owner	Nov 18 '25	Sale	8.79	19,341	170,048	3,744,741	Nov 20 04:07 PM
Southpoint Capital Advisors LP	10% Owner	Nov 14 '25	Sale	8.00	160,100	1,280,432	3,850,000	Nov 17 08:42 PM
Southpoint Capital Advisors LP	10% Owner	Nov 17 '25	Sale	8.79	85,918	755,193	3,764,082	Nov 17 08:42 PM
Raykov Rosty	Director	Nov 05 '25	Sale	8.10	10,000	81,000	82,318	Nov 06 04:10 PM
ROSTISLAV RAYKOV	Director	Nov 05 '25	Proposed Sale	8.11	10,000	81,082		Nov 05 04:28 PM
RALLIS CHRIS A	Director	Oct 10 '25	Option Exercise	1.23	4,062	4,996	58,854	Oct 14 04:10 PM
RALLIS CHRIS A	Director	Oct 10 '25	Sale	9.24	1,775	16,401	57,079	Oct 14 04:10 PM
CHRIS A RALLIS	Director	Oct 10 '25	Proposed Sale	9.24	1,775	16,401		Oct 10 04:02 PM
Southpoint Capital Advisors LP	10% Owner	Oct 07 '25	Sale	9.59	26,900	257,893	4,050,314	Oct 09 05:31 PM
Southpoint Capital Advisors LP	10% Owner	Oct 09 '25	Sale	9.35	20,609	192,614	4,010,100	Oct 09 05:31 PM
Southpoint Capital Advisors LP	10% Owner	Oct 08 '25	Sale	9.47	19,605	185,722	4,030,709	Oct 09 05:31 PM
Raykov Rosty	Director	Oct 08 '25	Option Exercise	2.45	4,609	11,292	87,110	Oct 08 05:08 PM
Raykov Rosty	Director	Oct 06 '25	Sale	9.78	10,000	97,800	82,501	Oct 06 06:22 PM
ROSTISLAV RAYKOV	Director	Oct 06 '25	Proposed Sale	9.79	10,000	97,868		Oct 06 04:27 PM
Raykov Rosty	Director	Sep 05 '25	Option Exercise	2.45	36,207	88,707	87,293	Sep 08 06:05 PM
ROSTISLAV RAYKOV	Director	Sep 04 '25	Proposed Sale	8.92	10,000	89,220		Sep 04 04:37 PM
Raykov Rosty	Director	Sep 04 '25	Sale	8.92	10,000	89,200	51,086	Sep 04 04:10 PM
Raykov Rosty	Director	Aug 05 '25	Sale	8.09	10,000	80,900	55,878	Aug 05 05:33 PM
ROSTISLAV RAYKOV	Director	Aug 05 '25	Proposed Sale	8.09	10,000	80,933		Aug 05 04:14 PM
RALLIS CHRIS A	Director	Jul 07 '25	Option Exercise	2.35	2,127	4,998	55,911	Jul 07 05:31 PM
RALLIS CHRIS A	Director	Jul 07 '25	Sale	8.71	1,119	9,746	54,792	Jul 07 05:31 PM
Raykov Rosty	Director	Jul 03 '25	Sale	8.61	10,000	86,100	60,670	Jul 07 04:30 PM
ROSTISLAV RAYKOV	Director	Jul 03 '25	Proposed Sale	8.61	10,000	86,102		Jul 03 02:01 PM
Raykov Rosty	Director	Jun 05 '25	Sale	7.78	10,000	77,800	65,462	Jun 06 04:20 PM
ROSTISLAV RAYKOV	Director	Jun 05 '25	Proposed Sale	7.78	10,000	77,781		Jun 05 04:31 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	May 22 '25	Option Exercise	5.10	8,220	41,922	158,520	May 23 04:20 PM
Hackman Jeffrey S.	Chief Executive Officer	May 19 '25	Buy	6.99	13,965	97,615	15,000	May 19 05:42 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FENC

Fennec Pharmaceuticals Inc

Upgrade your Finviz experience